SOPHiA GENETICS Expands US Reach with Major Health System Deals

BOSTON and ROLLE, Switzerland – February 10, 2026 – By Joyce Watson

SOPHiA GENETICS, a global healthcare technology company, today announced a significant expansion of its U.S. operations, securing partnerships with two of the nation's largest integrated health systems. The move signals a major step forward in the adoption of artificial intelligence for complex genomic analysis in mainstream American healthcare.

The two institutions, which remain unnamed but are described as a leading nonprofit multi-region system and a top 10 U.S. health system laboratory, will integrate the AI-powered SOPHiA DDM™ platform into their workflows. Initially, this collaboration will enable advanced genomic testing for up to 60,000 patients each year across the West Coast and Midwest, focusing on hereditary cancers and rare diseases.

This strategic alliance aims to harness the power of AI to analyze vast and complex genetic datasets at scale, a challenge that has often created bottlenecks in the delivery of precision medicine. By embedding the cloud-native platform directly into their laboratories, the health systems expect to accelerate diagnostic timelines, reduce operational costs, and bolster their internal research capabilities.

A Strategic Play in a Competitive Market

The partnerships represent a critical victory for SOPHiA GENETICS in the highly competitive AI-driven precision medicine market. The global market, estimated at $2.29 billion in 2024, is projected to soar to over $14.5 billion by 2030, with North America holding the largest revenue share. This deal solidifies the company's foothold in this crucial region, pitting it more directly against established competitors like Tempus, Illumina, and Foundation Medicine.

This expansion builds on a period of strong financial momentum for the company. SOPHiA GENETICS reported approximately $77 million in revenue for the full year 2025, an 18% increase over the previous year, and has issued optimistic guidance for 2026 with projected revenues between $92 million and $94 million. While the company is not yet profitable, its consistent year-over-year revenue growth and expanding customer base—which stood at 488 core genomics customers at the end of Q3 2025—demonstrate a clear strategy of scaling through platform adoption.

The company’s focus on the U.S. has been particularly fruitful, with its American revenue growing 70% in 2023. This new agreement with two heavyweight healthcare providers, which collectively serve nearly one million cancer and rare disorder patients annually, significantly deepens that penetration and validates the growing demand for scalable, decentralized AI solutions in clinical settings.

The Technology Driving the Change

At the core of the collaboration is the SOPHiA DDM™ platform, a sophisticated tool designed to untangle the complexities of genomic data. Both health systems will specifically leverage the Enhanced Exome application, an AI-driven analytic module capable of performing a comprehensive analysis of over 20,000 genes while also allowing for deeper investigation into specific regions of clinical interest.

For laboratories, this technology promises a paradigm shift. Instead of cumbersome, multi-stage testing protocols, the platform offers the potential to consolidate analysis into a single, streamlined process. This not only speeds up results but also reduces the operational burden on labs struggling with increasing sample volumes.

"Partnering with two of the largest health systems in the U.S. underscores the growing need for AI-powered genomic solutions capable of addressing increasingly complex use cases that can scale without adding operational burden," said John Carey, Managing Director for North America at SOPHiA GENETICS. "Combining advanced bioinformatics, the collective knowledge of a global community, and streamlined workflows, our AI enables healthcare institutions to unlock deeper insights."

New Hope for Patients and Lingering Ethical Questions

Beyond the business and technology, the most profound impact of this expansion is on patients. For individuals and families navigating the uncertainty of a potential hereditary cancer or a difficult-to-diagnose rare disease, time is a critical factor. The ability to accelerate a diagnosis from months to weeks can fundamentally alter treatment pathways and outcomes, providing clarity and enabling clinicians to deploy personalized therapies sooner.

By bringing advanced full-exome analysis to a potential 60,000 new patients annually, this initiative represents a tangible step toward democratizing data-driven medicine, moving it from niche academic centers into the broader healthcare landscape.

However, the rapid integration of AI into genomics is not without its challenges. The processing of vast amounts of highly sensitive genetic data raises significant ethical and privacy concerns. Genomic information reveals intimate details not only about an individual but also about their family members and future generations. Experts caution that even anonymized data carries a risk of re-identification, and the potential for misuse by insurers or other entities could erode public trust.

Ensuring patient privacy requires robust security measures, including advanced encryption and strict access controls, that go beyond standard interpretations of regulations like the Health Insurance Portability and Accountability Act (HIPAA). Securing truly informed consent—where patients fully understand how their data will be used by complex AI algorithms now and in the future—remains a significant hurdle for the entire industry.

This collaboration positions both SOPHiA GENETICS and its new partners at the forefront of innovation, but also places them on the front lines of navigating these critical ethical questions. The company's future growth, which includes strategic partnerships with other leading institutions like The University of Texas MD Anderson Cancer Center, will depend not only on the power of its technology but also on its ability to build a trusted framework for its use. With over $400 million invested in its platform, SOPHiA GENETICS is betting that its scalable, decentralized model is the key to unlocking the future of personalized medicine across the globe.